An MRI Ancillary Study of Malaria Fever Control RCT
An MRI Ancillary Study of Malaria Fever Control RCT
批准号:
10117293
负责人:
GRETCHEN L. BIRBECK
金额:
$28.27万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2020
资助国家:
美国
项目状态:
未结题
起止时间:
2020-03-15 至 2025-01-31
关键词:
AcetaminophenAcuteAdverse effectsAdverse eventAffectAfricanAgeAncillary StudyAnti-Inflammatory AgentsAntiinflammatory EffectAutopsyBehavior assessmentBlindedBloodBrainBrain InjuriesCaringChildChild CareChildhoodClinical TreatmentClinical TrialsClinical Trials Data Monitoring CommitteesDataEarly identificationEnrollmentEvaluationEvolutionFeverFutureGoalsGuidelinesHemorrhageHemosiderinIbuprofenImageInfrastructureInjuryInterventionIntervention TrialIntraventricularLesionLinkLocationLongterm Follow-upMagnetic Resonance ImagingMalariaMalawiMediatingMethodsNegative FindingNeurologicNeurological outcomeOutcomePathway interactionsPhasePopulationPrevalencePropertyProxyRandomized Controlled TrialsRecoveryResearchResearch DesignResidual stateRiskRisk FactorsSeveritiesStainsStructural defectStructureTemperatureZambiaacute infectionantipyreticbaseblood productbrain abnormalitiescognitive testingdesignfollow-upinsightmalaria infectionneuroimagingneuroprotectionprimary outcomeprogramsradiologistresponseroutine carescale uptooltreatment as usualtreatment responsetreatment-related injury
中文摘要
联系PD/PI:BIRBECK,Gretchen L.
摘要
尽管有根除疟疾的努力,但在非洲,仍有约40万名非洲儿童因中枢神经系统疟疾而遭受脑损伤。
2016.急性疟疾感染期间较高的最高温度(Tmax)是一个确定的危险因素,
神经系统后遗症和一项随机对照试验(RCT)的积极解热治疗,
对乙酰氨基酚和布洛芬于2019年开始在马拉维招募(R 01 NS 102176),并扩展到
赞比亚待定。在这项临床试验中,主要结局是急性感染期间的Tmax。但
在该RCT中使用的退热疗法可以提供神经保护益处而不影响Tmax-例如,
通过抗炎机制进行神经保护。在这项辅助研究中,我们建议使用
在RCT的背景下进行神经影像学检查,以进一步评估侵袭性神经保护剂的潜在神经保护作用。
解热治疗中枢神经系统疟疾,并探讨这些影响的可能机制。比较儿童
分配到积极的解热治疗与常规护理对结构性脑异常的患病率
在从CNS疟疾中恢复后,将有助于评估用于神经保护的非发热途径。两
赞比亚和马拉维在学术领域的先进成像方面拥有异常发达的基础设施,
脑部MRI将于
在恢复后1个月和12个月入组RCT的儿童。将完成分析,
基于RCT治疗分配和基于(Tmax)分层的任何结构性损伤的几率
治疗分配,以评估与治疗反应(发热减少)特别相关的变化。
将评价侵袭性解热相关损伤的潜在机制,包括评估
治疗相关CNS出血。神经影像学检查是一种公认的、有效的神经功能结局替代方法,
脑损伤,包括小儿中枢神经系统疟疾。将该MRI辅助研究添加到我们的发热RCT中,
治疗相关损伤的机制,并允许早期识别神经保护,
使用退烧药,否则需要长期随访进行认知和行为评估。这
将MRI辅助研究添加到发热RCT中时,将提供重要见解,可为未来的研究提供信息。
疟疾的神经保护研究可能会结合成像来优化研究设计。
将进行使用积极退热治疗的RCT的中心。
第7页
项目概要/摘要
英文摘要
Contact PD/PI: BIRBECK, GRETCHEN L.
ABSTRACT
Despite eradication efforts, ~400,000 African children sustained brain injuries as a result of CNS malaria in
2016. A higher maximum temperature (Tmax) during the acute malaria infection is an established risk factor for
neurologic sequelae and a randomized controlled trial (RCT) of aggressive antipyretic therapy with
acetaminophen and ibuprofen began enrollment in Malawi in 2019 (R01NS102176) with expansion into
Zambia pending. In this clinical trial, the primary outcome is Tmax during the acute infection. However, the
antipyretic therapies used in this RCT may offer neuroprotective benefits without affecting Tmax--for example,
neuroprotection through anti-inflammatory mechanisms. In this ancillary study, we propose to use
neuroimaging in the context of the RCT to further evaluate the potential neuroprotective effects of aggressive
antipyretic therapy for CNS malaria and explore possible mechanisms for these effects. Comparing children
allocated to aggressive antipyretic therapy vs. usual care on the prevalence of structural brain abnormalities
after recovery from CNS malaria will facilitate the evaluation of non-fever pathways for neuroprotection. Both
Zambia and Malawi have an unusually well developed infrastructure for advanced imaging in the academic
Brain MRIs will be obtained in
children enrolled in the RCT at 1- and 12-months post recovery. Analyses will be completed comparing the
odds of having any structural injury based upon RCT treatment allocation and based upon (Tmax) stratified by
treatment allocation to assess changes specifically related to response to therapy in terms of fever reduction.
Potential mechanisms of aggressive antipyretic-related injury will be evaluated including assessments for
treatment-related CNS bleeds. Neuroimaging is a well-established, valid proxy for neurological outcomes after
brain injury including in pediatric CNS malaria. Adding this MRI ancillary study to our fever RCT may elucidate
mechanisms of treatment-associated injury and allow for early identification of neuroprotection from aggressive
antipyretic use that would otherwise require long-term follow-up for cognitive and behavioral assessments. This
MRI ancillary study when added to the Fever RCT will provide critical insights that could inform future
neuroprotective studies of malaria that might incorporate imaging to optimize study design.
centers where the RCT using aggressive antipyretic therapy will be conducted.
Page 7
Project Summary/Abstract
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Global Research Endeavors to Advance Treatment of Neurological Disorders in Africa (GREAT Neurology)
-
批准号:10611348
-
项目类别:
-
资助金额:$52.72万
-
财政年份:2021
-
负责人:GRETCHEN L. BIRBECK
-
依托单位:
Global Research Endeavors to Advance Treatment of Neurological Disorders in Africa (GREAT Neurology)
-
批准号:10397647
-
项目类别:
-
资助金额:$52.19万
-
财政年份:2021
-
负责人:GRETCHEN L. BIRBECK
-
依托单位:
Global Research Endeavors to Advance Treatment of Neurological Disorders in Africa (GREAT Neurology)
-
批准号:10238395
-
项目类别:
-
资助金额:$44.78万
-
财政年份:2021
-
负责人:GRETCHEN L. BIRBECK
-
依托单位:
An MRI Ancillary Study of Malaria Fever Control RCT
-
批准号:10343754
-
项目类别:
-
资助金额:$24.66万
-
财政年份:2020
-
负责人:GRETCHEN L. BIRBECK
-
依托单位:
An MRI Ancillary Study of Malaria Fever Control RCT
-
批准号:10556361
-
项目类别:
-
资助金额:$24.55万
-
财政年份:2020
-
负责人:GRETCHEN L. BIRBECK
-
依托单位:
Collaborative HIV Investigations of Antiretroviral Neuropsychiatric Toxicities in Zambia (CHANTZ): Protease Inhibitor Impact on Pediatric Cerebrovasculature and Mood
-
批准号:10252756
-
项目类别:
-
资助金额:$16.58万
-
财政年份:2020
-
负责人:GRETCHEN L. BIRBECK
-
依托单位:
Collaborative HIV Investigations of Antiretroviral Neuropsychiatric Toxicities in Zambia (CHANTZ): Protease Inhibitor Impact on Pediatric Cerebrovasculature and Mood
-
批准号:9925503
-
项目类别:
-
资助金额:$23.28万
-
财政年份:2020
-
负责人:GRETCHEN L. BIRBECK
-
依托单位:
An MRI Ancillary Study of Malaria Fever Control RCT
-
批准号:9884625
-
项目类别:
-
资助金额:$31.75万
-
财政年份:2020
-
负责人:GRETCHEN L. BIRBECK
-
依托单位:
Aggressive Antipyretics in CNS Malaria: A Randomized-Controlled Trial Assessing Antipyretic Efficacy and Parasite Clearance
-
批准号:9923006
-
项目类别:
-
资助金额:$63.88万
-
财政年份:2017
-
负责人:GRETCHEN L. BIRBECK
-
依托单位:
Aggressive Antipyretics in CNS Malaria: A Randomized-Controlled Trial Assessing Antipyretic Efficacy and Parasite Clearance
-
批准号:10179500
-
项目类别:
-
资助金额:$60.25万
-
财政年份:2017
-
负责人:GRETCHEN L. BIRBECK
-
依托单位:
Cohort of HIV-Associated Seizures and Epilepsy in Zambia (CHASE): Scale up and expansion informed by R21 Findings
-
批准号:9336983
-
项目类别:
-
资助金额:$56.09万
-
财政年份:2015
-
负责人:GRETCHEN L. BIRBECK
-
依托单位:
Cohort of HIV-Associated Seizures and Epilepsy in Zambia (CHASE): Scale up and expansion informed by R21 Findings
-
批准号:8990936
-
项目类别:
-
资助金额:$61.91万
-
财政年份:2015
-
负责人:GRETCHEN L. BIRBECK
-
依托单位:
Cohort of HIV-Associated Seizures and Epilepsy in Zambia (CHASE): Scale up and expansion informed by R21 Findings
-
批准号:9927078
-
项目类别:
-
资助金额:$13.76万
-
财政年份:2015
-
负责人:GRETCHEN L. BIRBECK
-
依托单位:
Cohort of HIV-Associated Seizures and Epilepsy in Zambia (CHASE): Scale up and expansion informed by R21 Findings
-
批准号:9751402
-
项目类别:
-
资助金额:$57.51万
-
财政年份:2015
-
负责人:GRETCHEN L. BIRBECK
-
依托单位:
A DOSE-ESCALATION, SAFETY AND FEASIBILITY STUDY OF ENTERAL LEVETIRACETAM FOR SEIZ
-
批准号:8302847
-
项目类别:
-
资助金额:$71.22万
-
财政年份:2012
-
负责人:GRETCHEN L. BIRBECK
-
依托单位:
A Dose-Escalation, Safety and Feasibility Study of Enteral Levetiracetam for Seizure Control in Pediatric Cerebral Malaria
-
批准号:8739553
-
项目类别:
-
资助金额:$54.7万
-
财政年份:2012
-
负责人:GRETCHEN L. BIRBECK
-
依托单位:
A Dose-Escalation, Safety and Feasibility Study of Enteral Levetiracetam for Seizure Control in Pediatric Cerebral Malaria
-
批准号:8714332
-
项目类别:
-
资助金额:$57.23万
-
财政年份:2012
-
负责人:GRETCHEN L. BIRBECK
-
依托单位:
A Cohort Study of Seizures and Epilepsy in HIV+ Zambian Adults
-
批准号:8217127
-
项目类别:
-
资助金额:$11.9万
-
财政年份:2011
-
负责人:GRETCHEN L. BIRBECK
-
依托单位:
A Cohort Study of Seizures and Epilepsy in HIV+ Zambian Adults
-
批准号:8073288
-
项目类别:
-
资助金额:$12.58万
-
财政年份:2011
-
负责人:GRETCHEN L. BIRBECK
-
依托单位:
THE MALAWI-MSU MRI PROJECT: AN EPIDEMIOLOGIC STUDY OF CNS ABNORMALITIES
-
批准号:8133641
-
项目类别:
-
资助金额:$5.42万
-
财政年份:2010
-
负责人:GRETCHEN L. BIRBECK
-
依托单位:
海外基金